We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Cardiovascular Systems Inc

Cardiovascular Systems Inc (CSII)

( 0.00% )
Updated: 20:00:00

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.00 Day's Range 0.00
19.96 52 Week Range 20.00
Previous Close
Last Trade
Last Trade Time
Average Volume (3m)
Financial Volume

CSII Latest News

Cytek Biosciences Set to Join S&P SmallCap 600

Cytek Biosciences Set to Join S&P SmallCap 600 PR Newswire NEW YORK, April 25, 2023 NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
NIVFNewGenIvf Group Ltd
$ 2.195
$ 2.2502
OPRTOportun Financial Corporation
$ 3.22
HKITHitek Global Inc
$ 1.355
POETPOET Technologies Inc
$ 1.65
ABEOAbeona Therapeutics Inc
$ 3.395
GWAVGreenwave Technology Solutions Inc
$ 0.0691
LICNLichen China Limited
$ 0.569
MLECMoolec Science SA
$ 1.70
TIRXTian Ruixiang Holdings Ltd
$ 0.50
$ 0.1096
PEGYPineapple Energy Inc
$ 0.056525
NIVFNewGenIvf Group Ltd
$ 2.19
SQQQProShares UltraPro Short QQQ
$ 11.8703
TSLATesla Inc
$ 145.07

CSII Discussion

View Posts
MomsSpaghetti MomsSpaghetti 1 year ago
Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million
by admin February 9, 2023
Cardiovascular Systems NASDAQ CSII Acquired By Abbott Labs NYSE ABT Spotlight Growth
Cardiovascular Systems NASDAQ CSII Acquired By Abbott Labs NYSE ABT Spotlight Growth
Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and commercialization of novel solutions to treat coronary and vascular diseases. Shares of the heart medical device company are surging 48% through early trading on Thursday, February 9, 2023. Over the past three months, Cardiovascular Systems has seen average daily volume of 260,730 shares. However, volume of 5.16 million shares or dollar volume of around $101.7 million, has already exchanged hands through early trading.

Shares of Cardiovascular Systems are rallying after the company announced it has entered into a definitive agreement to be acquired by Abbott Labs (NYSE: ABT) for $20 per share or a total transaction value of $890 million. With the acquisition, Abbott Labs will leverage Cardiovascular Systems’ atherectomy platform, which prepares vessels for angioplasty or stenting. CSII’s platform will serve as a complementary solution to Abbott’s existing vascular disease assets.

Cardiovascular Systems is considered to be an industry leader with its atherectomy devices, which can treat plaque build-up in the arteries through a minimally invasive treatment process. Furthermore, the heart medical device company has an enticing pipeline of early-stage vascular intervention devices that would serve as a complement to its existing platform.

Abbott says the transaction is expected to have a neutral impact to the company’s recently issued 2023 guidance. The transaction still requires approval from Cardiovascular Systems shareholders and regulatory agencies.

“We are pleased to have reached an agreement with a leading global company that shares our passion for the development and commercialization of innovative solutions for treating complex peripheral vascular disease and coronary artery disease,” said Scott Ward, CSI’s chairman, president and chief executive officer. “We believe combining with Abbott delivers value to our patients, physician customers, employees and stockholders while continuing our work to save limbs and save lives every day.”
Hawkeye_tt Hawkeye_tt 4 years ago

Cardiovascular Systems Prices Public Offering of Common Stock
June 09 2020 - 10:32PM
Business Wire Print
Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced the pricing of its previously announced underwritten public offering of 3,676,471 shares of its common stock at a price to the public of $34.00 per share. Gross proceeds to CSI from the offering are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In connection with the offering, CSI has granted to the underwriters of the offering a 30-day option to purchase up to an additional 551,470 shares of common stock at the same price to the public. The offering is expected to close on June 12, 2020, subject to customary closing conditions.
whytestocks whytestocks 5 years ago
News: $CSII Cardiovascular Systems, Inc. to Present at Three Upcoming Investor Conferences

Cardiovascular Systems, Inc. (CSI ® ) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that management will present and host investor meetings a...

Find out more
Hawkeye_tt Hawkeye_tt 7 years ago
??? Today.
r clarke r clarke 8 years ago
Agree there are some positive moves being made. My concern is that the recent spike was a bit " too much , too soon " and overly euphoric.
I think the pps will slide a bit from here.

Company continues to lose money, and now has the distraction of multiple lawsuits to contend with. Losses are projected to continue.

"The shareholder class action complaint alleges that CSI and certain of its executive officers made a series of false and misleading statements and failed to disclose material adverse facts about the Company's business and operations. Specifically, the defendants are alleged to have falsely touted CSI's code of ethics while failing to disclose that the Company relied upon illegal kickbacks, off-label promotions, and other violations of applicable laws and regulations in order to drive sales of its products."
Shavasana Shavasana 9 years ago
TREND1 TREND1 9 years ago
The company’s second-quarter revenues increased 38 percent to $44.7 million, from $32.3 million in the second quarter of fiscal 2014. Coronary revenues grew to $6.3 million. Customer reorder revenues remained strong at 95 percent of total revenue, compared to 96 percent a year ago. The gross profit margin increased to 79 percent from 77 percent, benefiting from higher average selling prices of coronary products and lower device unit costs than in the prior-year quarter.

CSI’s fiscal 2015 second-quarter net loss was $(5.3) million, or $(0.17) per common share, compared to a net loss of $(8.7) million, or $(0.32) per common share, in the fiscal 2014 second quarter. Adjusted EBITDA improved to $(1.3) million compared to $(4.6) million a year earlier. Losses narrowed from the prior year as revenue gains exceeded the growth of planned investments, including over $12 million related to the coronary market. Overall, expenses were favorable to guidance, due to lower than expected expenses for sales force expansion and timing of projects. Excluding net coronary investments, adjusted EBITDA was positive for the quarter.
TREND1 TREND1 9 years ago

Sellthem Sellthem 10 years ago
Thanks for the heads up
shark44 shark44 10 years ago
My brother told me about this Stock. He was in on the preferred shares around $5 before the IPO. When it went down to around $3.50 I loaded up. Take a look at SWFT. Have been in since $7 around $22 now. This used to be a great stock to trade in and out. I also play some Pennies for fun. Good Luck SELLTHEM
Sellthem Sellthem 10 years ago
Yep I think over 12 months we will see above $50
shark44 shark44 10 years ago
This Company has been MONEY$$$$ in the BANK
Sellthem Sellthem 10 years ago
It's looking good :)
shark44 shark44 10 years ago
This Company keeps on Moving. I have been in since July of 2010 around $4 back then.
Sellthem Sellthem 11 years ago
Nice pop this morning FDA approval
MarkHB MarkHB 11 years ago
I have a nice profit 45% on this stock. Letin her ride for awhile.
mlkrborn mlkrborn 12 years ago
Cardiovascular Systems reports data from Compliance 360 study comparing orbital atherectomy vs. percutaneous transluminal angioplasty (CSII) 9.08 +0.02 : Study shows that by avoiding stents and reducing restenosis saves money - approximate incremental cost effectiveness of the Diamondback group vs. the percutaneous transluminal angioplasty group at six months was $5,264 per additional acute adjunctive stenting or restenosis avoided... The percutaneous transluminal angioplasty arm required bail-out stenting in 84% of the procedures to achieve results equivalent to the Diamondback arm. Diamondback procedures had lower dissection rates and reduced bail-out stenting, thus preserving future treatment options.
Penny Roger$ Penny Roger$ 12 years ago
Surf adds much much dimension as well. I am glad to assist imo.

I also thank you for the compliments. Options.. Covering.. Expiration.. I am sure there are many Dungeons and Dragons fans in this market place.
mlkrborn mlkrborn 12 years ago
MAC; You do a great service ! You added a new dimension --essential one--to all the bio boards Surf is moderating. But better methodology is to correlate options gambling with earnings guestimates, it seems. I noticed they do it on the fast money program. I dont know much about options gambling. But it could be nice,at least, to follow up on yur timely earnings report warnings and provide concrete numbers on financials of cos.
keep up ith good work!
Penny Roger$ Penny Roger$ 12 years ago
<<< $CSII Links! >>> ~ MAC's Quick DD Links without the charts.

PennyStockTweets ~

OTC Markets Company Info ~
OTC Markets Charts ~
OTC Markets Quote ~
OTC Markets News ~
OTC Markets Financials ~
OTC Markets Short Sales ~
OTC Markets Insider Disclosure ~
OTC Markets Research Reports ~

Google Finance Summary ~
Google Finance News ~
Google Finance Option chain ~
Google Finance Financials ~
Google Finance Historical prices Daily ~
Google Finance Historical prices Weekly ~

Y! < Company >
Y! Profile ~
Y! Key Stat's ~
Y! Headlines ~
Y! Summary ~
Y! Historical Prices ~
Y! Order Book ~
Y! Message Boards ~
Y! Market Pulse ~
Y! Technical Analysis ~
Y! < Analyst Coverage >
Y! Analyst Opinion ~
Y! Analyst Estimates ~
Y! Research Reports ~
Y! Star Analysts ~
Y! < Ownership >
Y! Major Holders ~
Y! Insider Transactions ~
Y! Insider Roster ~
Y! < Financials >
Y! Income Statement ~
Y! Balance Sheet ~
Y! Cash Flow ~


Investorshub Trades ~
Investorshub Board Search ~
Investorshub PostStream ~
Investorshub Messages ~
Investorshub Videos ~
Investorshub News ~

CandlestickChart ~

Barchart Quote ~
Barchart Detailed Quote ~
Barchart Options Quotes ~
Barchart Technical Chart ~
Barchart Interactive Chart ~
Barchart Technical Analysis ~
Barchart Trader's Cheat Sheet ~
Barchart Barchart Opinion ~
Barchart Snapshot Opinion ~
Barchart News Headlines ~
Barchart Profile ~
Barchart Key Statistics ~

OTC: American Bulls ~
NASDAQ: American Bulls ~
NYSE: American Bulls ~

Marketwatch Profile ~
Marketwatch Analyst Estimates ~
Marketwatch Historical Quotes ~
Marketwatch Financials ~
Marketwatch Overview ~
Marketwatch SEC Filings ~
Marketwatch Picks ~
Marketwatch Hulbert ~
Marketwatch Insider Actions ~
Marketwatch Options ~
Marketwatch Charts ~
Marketwatch News ~

The Lion ~

Search NYSE ~

StockTA ~

StockHouse ~
StockHouse Delayed LII ~

AlphaTrade ~

Reuters ~

StockWatch ~®ion=U

Search NASDAQ ~
NASDAQ Divy History ~
NASDAQ Short Interest ~
NASDAQ Institutional Ownership ~
NASDAQ FlashQuotes ~
NASDAQ InfoQuotes ~
NASDAQ After Hours Quote ~
NASDAQ Pre-Market Quote ~
NASDAQ Historical Quote ~
NASDAQ Option Chain ~
NASDAQ Company Headlines ~
NASDAQ Press Releases ~
NASDAQ Sentiment ~
NASDAQ Analyst Summary ~
NASDAQ Guru Analysis~
NASDAQ Stock Report ~
NASDAQ Competitors ~
NASDAQ Stock Consultant ~
NASDAQ Stock Comparison ~
NASDAQ Call Transcripts ~
NASDAQ Annual Reports ~
NASDAQ Financials ~
NASDAQ Revenue & Earnings Per Share (EPS) ~
NASDAQ SEC Filings ~
NASDAQ Ownership Summary ~
NASDAQ Institutional Ownership ~
NASDAQ (SEC Form 4) ~
--------- All Trades ~
--------- Buys ~
--------- Sells ~

The Motley Fool ~
The Motley Fool Earnings/Growth ~
The Motley Fool Ratios ~
The Motley Fool Stats ~
The Motley Fool Historical ~
The Motley Fool Scorecard ~
The Motley Fool Statements ~

MSN Money ~

YCharts ~
YCharts Performance ~
YCharts Dashboard ~

InsideStocks Opinion ~
InsideStocks Profile ~
InsideStocks Quote ~
InsideStocks Projection ~

Zacks Quote ~
Zacks Estimates ~
Zacks Company Reports ~

Knobias ~

StockScores ~

Trade-Ideas ~

Morningstar ~
Morningstar Shareholders ~®ion=USA&culture=en-us
Morningstar Transcripts~®ion=USA
Morningstar Key Ratios ~®ion=USA&culture=en-US
Morningstar Executive Compensation ~®ion=USA&culture=en-us
Morningstar Valuation ~®ion=USA&culture=en-us

CCBN (Thompson Reuters) ~

TradingMarkets ~


Insidercow ~

Forbes News ~
Forbes Press Releases ~,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~

YouTube Symbol Search ~

Buy-Ins ~

Quotemedia ~

Earnings Whispers ~

Bloomberg Snapshot ~
Bloomberg People ~

Financial Times ~

Investorpoint ~ enter "CSII" and click search.

Hotstocked ~ enter "CSII" and click search.

Raging Bull ~

Hoovers ~

DD Machine ~

SEC Form 4 ~

OTCBB Pulse ~

Failures To Deliver ~ enter "CSII" and click search.

DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
Check those searches for recent CSII mentions. If CSII is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
For a complete list see the pinned threads at the top here --->

Penny Roger$ Penny Roger$ 12 years ago
I also post charts in those reports and others can share thoughts and often do when that happens. Sometimes I see some nice double bottoms in these.

Have a DD as well.. Another work in progress to help others I guess. Very Bullish market here! Cheers!
mlkrborn mlkrborn 12 years ago
Mac Dgvyer; Its great to let us know upcoming reports. Equally important are reports themelves tho. You tend to dropp the subject after your annoncements.. Why?what is your purpose in follawing just upcoming reports?
mlkrborn mlkrborn 12 years ago
Cardiovascular Systems presents favorable results of DiamondbackTM Orbital Atherectomy System compared to balloon angioplasty alone (CSII) 9.24 : Co provides favorable results of the Diamondback Orbital Atherectomy System compared to balloon angioplasty alone included: Freedom from bailout stenting of 92% compared to 16%; Freedom from restenosis or retreatment, including the need for bailout stenting, of 73% versus 8% at 6 months; Comparable 12-month patency with far less need for adjunctive stenting in the Diamondback arm.
Penny Roger$ Penny Roger$ 12 years ago
~ $CSII ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CSII ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.

~ Barchart:
~ OTC Markets:
~ Google Finance:
~ Google Fin Options: h
~ Yahoo! Finance ~ Stats:
~ Yahoo! Finance ~ Profile:
~ BusyStock:
~ CandlestickChart:
~ Investorshub Trades:
~ Investorshub Board Search:
~ Investorshub PostStream Search:
~ Investorshub Goodies Search:
~ Investorshub Message Search:
~ MarketWatch:
~ E-Zone Chart:
~ 5-Min Wind:
~ 10-Min Wind:
~ 30-Min Wind:
~ 60-Min Wind:

*If the earnings date is in error please ignore error. I do my best.
TOUCAN TOUCAN 12 years ago
Hammer1 Hammer1 12 years ago
chopp chopp 12 years ago
I have this one figured out now..........Buy and sell indicator = Glen David Nelson.....
Hammer1 Hammer1 12 years ago

golfndude golfndude 12 years ago
$10 sweet
Hammer1 Hammer1 12 years ago
Big VOL on a FRI. Market SELLING OFF.....Im expecting some BIGSLY NEWS OUT NEXT WEEK....Oh and can you say CHART MOMO...Hammer
Hammer1 Hammer1 12 years ago
Gots to be SOMETHING GOING ON HERE.....watching thousands and thousands of ASK SLAPPING HITS and it barely moves on LOTS SHOWING 100 or 200......SUMSUP..........RUMER MILL MAY BE CORRECTO. Hammer
Hammer1 Hammer1 12 years ago
RUMOR MILL OF BUYOUT BEING FLUNG AROUND IN SOME CHAT ROOMS......Hmmmmmmmmmmmmmmmmmm that would be SICK. Hammer
Hammer1 Hammer1 12 years ago
CSII now coming back here. DONT BITCH A BITCH.....this one is GOLDEN. Hammer
alfaspider alfaspider 13 years ago
Oh MY MY MY....

Guess the Rev Jones and his front-loaded pink is at least holding its own?

Hammer1 Hammer1 13 years ago
SOB................... GOOD MAN....HAMMER
chopp chopp 13 years ago
Looks like Discovery added over 1million more.......
alfaspider alfaspider 13 years ago
Cardiovascular Systems Inc. (CSII, $7.58, -$2.72, -26.41%) reduced its forecast for the fiscal first quarter, pointing to a decline in procedures for peripheral arterial disease and their shift to physician-office-based labs from hospitals.

No wonder all the insiders were dumping their shares...........


Hammeoids posts can be hazardious to your portfolio...

$King $King 13 years ago
CSII @ 7.58
mlkrborn mlkrborn 13 years ago
Down over $2 with preliminary financial report. Two downgrades but still buy!
Cardiovascular Systems Announces Preliminary First-Quarter Financial Results

Revenue of $18.7 Million Is Below Guidance Range, Grows 3 Percent Over Prior Year’s First Quarter

Company Still Expects Double-Digit Growth for the Full Year of Fiscal 2012

Conference Call Scheduled for Today, October 6, 2011, at 3:45 PM CT (4:45 PM ET)

Related Quotes
Symbol Price Change
CSII 8.16 -2.14

Press Release Source: Cardiovascular Systems, Inc. On Thursday October 6, 2011, 4:05 pm EDT

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII - News), a medical device company developing and commercializing innovative interventional treatment systems for vascular disease, today announced preliminary revenue of approximately $18.7 million for the fiscal 2012 first quarter ended September 30, 2011, compared with $18.2 million in the first quarter of fiscal 2011.

The fiscal 2012 first-quarter net loss is expected to be in the range of $(3.9) million to $(4.2) million, or $(0.22) to $(0.24) per common share, including approximately $(400,000), or $(0.02) per common share, of expenses related to conversion and valuation changes of convertible debt. Net loss was $(4.3) million, or $(0.28) per common share, in the fiscal 2011 first quarter.

CSI’s first-quarter results are preliminary and subject to the company’s management and independent auditors completing their customary quarterly review procedures.

David L. Martin, CSI president and chief executive officer, commented, “After five consecutive quarters of double-digit revenue growth, CSI’s growth slowed in the fiscal 2012 first quarter and was below our guidance. While we are still reviewing the results, we believe several factors disrupted growth in the short-term, but will lead to higher revenue growth in the future.”

The following factors affected first-quarter fiscal 2012 revenue growth:

1. PAD (peripheral arterial disease) procedures are shifting from hospitals to physician office-based labs. This transition is expected to increase the number of PAD procedures performed in the future. In the short-term, however, hospital-based procedures and related purchases are decreasing. Purchases in the new office-based labs are lagging, due to the time dedicated to open those facilities and to limited cash resources that constrain their inventory levels. Sales to these labs are also highly competitive, which extends selling cycles.
2. Customer demand for conversion to the Stealth 360° PAD System was stronger than expected. The Stealth 360° customer base grew more than 120 percent to 240 accounts in the just-completed quarter. This higher demand consumed selling time, as sales professionals installed the new device in accounts, and reduced purchases in the short-term, as customers transitioned inventory between product lines. The Stealth 360° also has significantly fewer crown configurations, reducing the number of devices the customer needs to have in inventory.
3. Significant changes are under way in sales and marketing. With the May 2011 addition of Kevin Kenny as executive vice president of sales and marketing, many important changes to the sales and marketing organization and programs are in progress. These changes are necessary to build a foundation for higher growth in the future, but can be disruptive initially.
4. A general decline in PAD procedures occurred. Typically, PAD surgical procedures slow down in the summer months. Several sources indicate that the decline was more significant in 2011. While CSI does not believe this was a major cause for the lower revenue in the quarter, it likely heightened the effect of the other factors identified.

Martin continued, “We believe the sluggish first-quarter revenue growth is temporary, and we expect double-digit revenue growth for the full fiscal year. In fact, revenue in the month of September improved significantly as the short-term effect of these factors began to subside, growing 14 percent over September 2010. We remain confident that the strength of our Stealth 360° in an underserved PAD market, supported by unprecedented clinical data demonstrating its excellent safety and effectiveness, will result in attractive, sustainable growth over the long term.”

CSI will update fiscal 2012 guidance and provide guidance for second quarter of fiscal 2012 during its first-quarter earnings announcement, expected to be in early November.

chopp chopp 13 years ago
Increases in Holdings
Cardiovascular Systems (CSII)
Discovery Equity owns 1,323,315 shares (8.1%) after buying 173,564 from Aug. 29 to Sept. 7 at $12.29 to $14.25 apiece.
Hammer1 Hammer1 13 years ago

chopp chopp 13 years ago
Lets get this one headed higher. 21 mil in Rev last qtr. Loaded pipeline.......
Hammer1 Hammer1 13 years ago
looking like CSII gonna BREAK HERE. Hammer
Hammer1 Hammer1 13 years ago
Hammer1 Hammer1 13 years ago
CSII gonna make MEDICAL HISTORY. Hammer
chopp chopp 13 years ago
Patient enrollment is cleared by fda on Orbit II.
chopp chopp 13 years ago
Stealth 360 is just now getting rolling bro. Rev's will continue to increase.
chopp chopp 13 years ago
They are building new facility in Texas in 2012.
chopp chopp 13 years ago
CSII is strongus maximus!
Hammer1 Hammer1 13 years ago
CSII earngs call was GREAT. Hammer

Your Recent History

Delayed Upgrade Clock